Related Experiment Video

Updated: Aug 14, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Florida newborn screening for galactosemia

T J DeClue1, J I Malone, T A Tedesco

  • 1University of South Florida, College of Medicine, Tampa.

The Journal of the Florida Medical Association
|June 1, 1991
PubMed

Insights

Galactosemia is a rare metabolic disorder affecting 1:50,000 newborns. Early diagnosis and treatment are crucial to prevent severe health issues and mortality in infants.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Galactosemia is an inborn error of metabolism impacting galactose-1-phosphate conversion.
  • Untreated galactosemia leads to severe morbidity and mortality in newborns.
  • Newborn screening in Florida utilizes a fluorescence assay for galactose-1-phosphate uridyltransferase (GALT) activity.

Purpose of the Study:

  • To highlight the importance of newborn screening for galactosemia.
  • To discuss factors influencing GALT enzyme activity and screening results.
  • To emphasize the need for carrier detection and genetic counseling for at-risk families.

Main Methods:

  • Newborn screening via fluorescence assay measuring GALT activity in dried blood spots.
  • Analysis of genetic factors and external influences on enzyme activity.
  • Recommendations for carrier detection and genetic counseling.

Main Results:

  • Galactosemia screening identifies infants requiring immediate intervention.
  • Variability in GALT activity can complicate diagnosis.
  • Heterozygous infants and their parents are candidates for carrier testing.

Conclusions:

  • Early detection of galactosemia through newborn screening is vital for preventing severe outcomes.
  • Understanding factors affecting GALT activity is key for accurate diagnosis.
  • Genetic counseling and carrier detection are essential for families with galactosemia concerns.

More Related Videos

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection06:11

Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection

Published on: May 17, 2024

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...